A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.

@article{Schmidt2012ADR,
  title={A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.},
  author={Mark Schmidt and Justine M. Kent and Ella J. Daly and Luc Janssens and Nancy van Osselaer and Gitta H{\"u}sken and Ion G Anghelescu and Luc van Nueten},
  journal={European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology},
  year={2012},
  volume={22 10},
  pages={721-33}
}
JNJ-37822681 is a novel, highly selective dopamine D₂ receptor antagonist characterized by a rapid dissociation rate from the dopamine D₂ receptor. This profile was hypothesized to confer antipsychotic efficacy and improved tolerability. In this 12-week study, the efficacy and safety of JNJ-37822681 were evaluated in patients with an acute exacerbation of schizophrenia, randomly assigned (1:1:1:1:1) to JNJ-37822681 (10-, 20- or 30-mg bid), olanzapine (15 mg once-daily), or placebo (for 6 weeks… CONTINUE READING